Welcome to our dedicated page for Crispr Therapeut SEC filings (Ticker: CRSP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
CRISPR Therapeutics AG (Nasdaq: CRSP) files detailed reports with the U.S. Securities and Exchange Commission that document its financial condition, clinical pipeline progress, collaborations, and capital markets activity. On this SEC filings page, Stock Titan aggregates CRSP’s regulatory documents and pairs them with AI-powered summaries to help readers interpret the implications of each filing.
For a gene editing biopharmaceutical company like CRISPR Therapeutics, annual reports on Form 10-K and quarterly reports on Form 10-Q typically describe the status of programs such as CASGEVY for sickle cell disease and transfusion-dependent beta thalassemia, in vivo liver editing candidates like CTX310 and CTX320, SyNTase-based CTX460 for alpha-1 antitrypsin deficiency, zugo-cel in autoimmune and oncology indications, and siRNA collaborations such as SRSD107/CTX611 with Sirius Therapeutics. These reports also outline risk factors, research and development priorities, and collaboration structures with partners including Vertex Pharmaceuticals.
Current reports on Form 8-K provide more focused updates on material events, such as quarterly financial results, business updates, and capital-raising actions. For example, recent 8-K filings describe the announcement of quarterly results and the use of an at-the-market equity program under an Open Market Sale Agreement with Jefferies to offer additional common shares under a shelf registration statement.
Investors can also use this page to monitor registration statements, prospectus supplements, and other offering-related filings that detail how CRISPR Therapeutics issues new equity, as well as any proxy materials that address governance and shareholder matters. Stock Titan’s tools surface new CRSP filings in near real time from EDGAR and apply AI-generated highlights so readers can quickly locate key disclosures on clinical data, collaboration terms, cash runway, and share issuance without reading every page.
CRISPR Therapeutics AG General Counsel and Secretary James R. Kasinger reported RSU vesting and a related share sale. On March 14, 2026, 6,875 restricted stock units converted into 6,875 common shares at $0.00 per share, as part of a 27,500-share RSU grant vesting annually from 2026 to 2029.
On March 16, 2026, he sold 3,450 common shares at $48.26 per share to cover tax withholding obligations under the company’s RSU Settlement Policy, which the footnote states was not a discretionary trade. After these transactions, he directly holds 91,240 common shares and 20,625 restricted stock units, with remaining shares subject to a lock-up agreement tied to the company’s convertible senior notes due 2031.
CRISPR Therapeutics AG Chief Executive Officer Samarth Kulkarni reported RSU vesting and a related tax sale. On March 14, 2026, 20,625 Restricted Stock Units vested and were converted into 20,625 Common Shares at a conversion price of $0.00 per share.
The vested RSUs are part of an 82,500-share award granted on March 14, 2025, scheduled to vest in four equal annual installments through March 14, 2029. On March 16, 2026, 10,349 Common Shares were sold at $48.26 per share to cover tax withholding obligations under the company’s RSU Settlement Policy, which the footnotes state does not represent a discretionary trade. After these transactions, Kulkarni directly holds 245,834 Common Shares and 61,875 Restricted Stock Units.
CRISPR Therapeutics completed a private offering of $600.0 million aggregate principal amount of convertible senior notes due 2031, generating approximately $585.2 million in net proceeds for general corporate purposes. The notes are senior unsecured obligations with an effective coupon of 1.125%, increased to 1.7308% to offset anticipated Swiss withholding tax.
Holders may convert at an initial rate of 13.0617 common shares per $1,000 principal amount, implying a conversion price of about $76.56 per share, a 45.0% premium to the $52.80 last reported sale price on the Nasdaq Global Market on March 10, 2026. Initially, a maximum of 11,363,580 common shares may be delivered upon conversion based on the initial maximum conversion rate.
The notes mature on March 1, 2031, pay interest semiannually starting September 1, 2026, and are redeemable at the company’s option on or after March 6, 2029 if share price conditions are met. They were sold in an unregistered Rule 144A private placement, and the shares issuable upon conversion are expected to be delivered in transactions exempt under Section 3(a)(9).
CRISPR Therapeutics AG General Counsel and Secretary James R. Kasinger reported an RSU vesting and related share sale. On March 10, 2026, he acquired 5,500 Common Shares at $0.00 per share through the exercise of Restricted Stock Units, reflecting part of a 22,000-share award granted on March 10, 2023.
On March 11, 2026, he sold 2,800 Common Shares at an average price of $52.80 per share. A footnote states these shares were sold to cover tax withholding obligations under the company’s RSU Settlement Policy and were not a discretionary trade. After these transactions, he directly owned 87,815 Common Shares.
CRISPR Therapeutics AG Chief Executive Officer Samarth Kulkarni reported compensation-related share activity. On March 10, 2026, 19,250 restricted stock units were exercised into 19,250 Common Shares at $0.00 per share, reflecting vesting of part of a prior equity award.
On March 11, 2026, 9,798 Common Shares were sold at $52.80 per share. A footnote explains this amount was required to be sold to cover tax withholding tied to the RSU vesting under the company’s RSU Settlement Policy, and therefore did not represent a discretionary trade. After these transactions, Kulkarni directly held 235,558 Common Shares.
CRISPR Therapeutics AG is raising capital through a private offering of $550 million aggregate principal amount of convertible senior notes due 2031, sold to qualified institutional buyers. The offering was upsized from a previously proposed $350 million.
The notes carry an effective coupon of 1.125%, increased to 1.7308% to offset anticipated Swiss withholding tax, and mature on March 1, 2031 unless earlier converted, redeemed or repurchased. They are initially convertible at 13.0617 common shares per $1,000 principal amount, implying a conversion price of about $76.56 per share, a roughly 45% premium to the $52.80 share price on March 10, 2026. CRISPR Therapeutics estimates net proceeds of approximately $536.3 million, or $585.2 million if the purchasers’ option is fully exercised, and plans to use the funds for general corporate purposes.
CRISPR Therapeutics AG Chief Executive Officer Samarth Kulkarni reported RSU vesting and a related share sale. On February 18, 2026, he acquired 13,250 Common Shares at $0.00 per share through the exercise/settlement of restricted stock units.
On February 19, 2026, he sold 6,967 Common Shares at an average price of $52.58 per share. A footnote explains that this sale was required to cover tax withholding obligations under the company’s RSU Settlement Policy and was not a discretionary trade. After these transactions, he directly held 226,106 Common Shares.
The restricted stock units were originally granted on February 18, 2022 for 53,000 Common Shares, vesting in four equal annual installments through February 18, 2026.
CRISPR Therapeutics AG General Counsel and Secretary James R. Kasinger reported a mix of equity transactions involving company stock. On February 18, 2026, he acquired 3,825 Common Shares through the exercise and settlement of restricted stock units at a price of $0.00 per share, increasing his direct holdings to 87,227 Common Shares. On February 19, 2026, 2,112 Common Shares were sold at an average price of $52.58 per share to cover tax withholding obligations related to the RSU vesting, as required by the company’s RSU Settlement Policy and not as a discretionary trade. After these transactions, he directly owned 85,115 Common Shares.
Orbis Investment Management Ltd and Allan Gray Australia Pty Ltd report beneficial ownership of 5,950,145 shares of CRISPR Therapeutics common stock, representing 6.2% of the class as of 12/31/2025. Orbis holds 5,934,328 shares and Allan Gray holds 15,817 shares, each with sole voting and dispositive power over its respective holdings.
Both firms are non-U.S. institutions equivalent to investment advisers and state that the securities are held in the ordinary course of business, not to change or influence control of CRISPR Therapeutics. Other persons have rights to receive dividends or sale proceeds on the shares each firm beneficially owns.
CRISPR Therapeutics describes its business as a leader in CRISPR/Cas9 gene-editing medicines, highlighted by CASGEVY, the first approved CRISPR-based therapy for severe sickle cell disease and transfusion‑dependent beta thalassemia in patients 12 and older across multiple regions.
The company outlines four core franchises: hemoglobinopathies, in vivo liver gene editing, allogeneic CAR T cell therapies for autoimmune diseases and oncology, and regenerative medicine for Type 1 diabetes. It estimates about 60,000 eligible SCD and TDT patients in key Western and Middle Eastern markets.
Pipeline updates include CTX310 in Phase 1b for cardiovascular disease, where a single-course treatment cut ANGPTL3 by up to 89%, triglycerides by up to 84%, and LDL by up to 87% in early data, and CTX611, a long‑acting siRNA Factor XI inhibitor now in Phase 2. Zugo‑cel, its next‑generation allogeneic CD19 CAR T, shows high response rates in relapsed or refractory large B‑cell lymphoma and early remission signals in systemic lupus erythematosus.